Articolul precedent |
Articolul urmator |
352 4 |
Ultima descărcare din IBN: 2023-06-11 23:08 |
SM ISO690:2012 CHIŞLARI, Lia, RUSSU, Eugen, GROPPA, Liliana, CAZAC, Victor, ROTARU, Larisa. Prevalența chlamydiei trachomatis în urină la pacienții de sex masculin cu spondilită anchilozantă. In: Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”, 21-23 octombrie 2020, Chişinău. Chişinău: USMF, 2020, p. 204. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu” 2020 | ||||||
Congresul "Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”" Chişinău, Moldova, 21-23 octombrie 2020 | ||||||
|
||||||
Pag. 204-204 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Background. Identifying individual parameters capable of predicting disease severity and therapeutic outcome in patients with AS is another priority. A better elucidation of the potential role of the individual microbiota in these diseases could be a promising tool worth exploring. Objective of the study. Comparison of the prevalence of Chlamydia trachomatis infections in patients with ankylosing spondylitis (AS), using DNA amplification assays. Material and Methods. The prevalence of C trachomatis infections was assessed in 32 patients with AS and in 18 controls with appropriate age and sex. Urine samples were tested by PCR. In addition, blood samples from patients with AS were tested for serum anti-C trachomatis antibodies (IgA and IgG). Results. No significant differences were found between cases and control in the prevalence of C trachomatis infections. No associations were found between C trachomatis antibodies and disease characteristics, except for acute anterior uveitis (AAU). Half of the men (50%) with AS were IgG positive and had a history of AAU compared to 12.5% IgG negative men (OR = 7.0; 95% confidence intervals: 1.1, 44.1). Conclusion. The prevalence of C trachomatis infections detected by DNA amplification tests available in patients with AS is not higher compared to the control group adjusted by sex and age. However, there appears to be an association between specific antibodies to C trachomatis and AAU. |
||||||
Cuvinte-cheie ankylosing spondylitis, Chlamydia trachomatis, spondilită anchilozantă, Chlamydia trachomatis |
||||||
|
Cerif XML Export
<?xml version='1.0' encoding='utf-8'?> <CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'> <cfResPubl> <cfResPublId>ibn-ResPubl-125381</cfResPublId> <cfResPublDate>2020</cfResPublDate> <cfStartPage>204</cfStartPage> <cfISBN></cfISBN> <cfURI>https://ibn.idsi.md/ro/vizualizare_articol/125381</cfURI> <cfTitle cfLangCode='RO' cfTrans='o'>Prevalența chlamydiei trachomatis în urină la pacienții de sex masculin cu spondilită anchilozantă</cfTitle> <cfKeyw cfLangCode='RO' cfTrans='o'>ankylosing spondylitis; Chlamydia trachomatis; spondilită anchilozantă; Chlamydia trachomatis</cfKeyw> <cfAbstr cfLangCode='EN' cfTrans='o'><p>Background. Identifying individual parameters capable of predicting disease severity and therapeutic outcome in patients with AS is another priority. A better elucidation of the potential role of the individual microbiota in these diseases could be a promising tool worth exploring. Objective of the study. Comparison of the prevalence of Chlamydia trachomatis infections in patients with ankylosing spondylitis (AS), using DNA amplification assays. Material and Methods. The prevalence of C trachomatis infections was assessed in 32 patients with AS and in 18 controls with appropriate age and sex. Urine samples were tested by PCR. In addition, blood samples from patients with AS were tested for serum anti-C trachomatis antibodies (IgA and IgG). Results. No significant differences were found between cases and control in the prevalence of C trachomatis infections. No associations were found between C trachomatis antibodies and disease characteristics, except for acute anterior uveitis (AAU). Half of the men (50%) with AS were IgG positive and had a history of AAU compared to 12.5% IgG negative men (OR = 7.0; 95% confidence intervals: 1.1, 44.1). Conclusion. The prevalence of C trachomatis infections detected by DNA amplification tests available in patients with AS is not higher compared to the control group adjusted by sex and age. However, there appears to be an association between specific antibodies to C trachomatis and AAU.</p></cfAbstr> <cfAbstr cfLangCode='RO' cfTrans='o'><p>Introducere. Identificarea parametrilor individuali capabili de a prezice severitatea bolii și rezultatul terapeutic la pacienții cu SA ramâne încă o prioritate. O mai bună elucidare a rolului potențial al microbiotei individuale în aceste boli ar putea fi un instrument promițător care merită să fie explorat. Scopul lucrării. Compararea prevalenței infecțiilor cu Chlamydia trachomatis la pacienții cu spondilită anchilozantă (SA), folosind analize de amplificare ADN. Material și Metode. Prevalența infecțiilor cu C. trachomatis a fost evaluată la 32 de pacienți cu SA și la 18 de control cu vârstă și sex potrivite. Probele de urină au fost testate prin PCR. În plus, probele de sânge ale pacienților cu SA au fost testate la anticorpii serici anti-C. trachomatis (IgA și IgG). Rezultate. Nu au fost găsite diferențe semnificative între cazuri și control în prevalența infecțiilor cu C. trachomatis. Nu s-au găsit asocieri între anticorpii C. trachomatis și caracteristicile bolii, cu excepția uveitei anterioare acute (UAA). Jumătate dintre bărbați (50%) cu SA au fost pozitivi pentru IgG și au avut un istoric de UAA în comparație cu 12,5% bărbați IgG negativi (OR = 7,0; 95% intervale de încredere: 1,1, 44,1). Concluzii. Prevalența infecțiilor cu C. trachomatis, detectate prin teste de amplificare ADN disponibile la pacienții cu SA nu este mai mare comparativ cu grupul de control ajustat după sex și vârstă. Cu toate acestea, pare să existe o asociere între anticorpii specifici față de C. trachomatis și UAA.</p></cfAbstr> <cfResPubl_Class> <cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId> <cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId> <cfStartDate>2020T24:00:00</cfStartDate> </cfResPubl_Class> <cfResPubl_Class> <cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId> <cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId> <cfStartDate>2020T24:00:00</cfStartDate> </cfResPubl_Class> <cfPers_ResPubl> <cfPersId>ibn-person-18889</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2020T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-29090</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2020T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-11727</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2020T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-36237</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2020T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-12009</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2020T24:00:00</cfStartDate> </cfPers_ResPubl> </cfResPubl> <cfPers> <cfPersId>ibn-Pers-18889</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-18889-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2020T24:00:00</cfStartDate> <cfFamilyNames>Chişlari</cfFamilyNames> <cfFirstNames>Lia</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-29090</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-29090-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2020T24:00:00</cfStartDate> <cfFamilyNames>Russu</cfFamilyNames> <cfFirstNames>Eugen</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-11727</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-11727-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2020T24:00:00</cfStartDate> <cfFamilyNames>Groppa</cfFamilyNames> <cfFirstNames>Liliana</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-36237</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-36237-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2020T24:00:00</cfStartDate> <cfFamilyNames>Kazak</cfFamilyNames> <cfFirstNames>Viktor</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-12009</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-12009-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2020T24:00:00</cfStartDate> <cfFamilyNames>Rotaru</cfFamilyNames> <cfFirstNames>Larisa</cfFirstNames> </cfPersName_Pers> </cfPers> </CERIF>